Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NanoVibronix Inc is a medical devices business based in the US. NanoVibronix shares (NAOV) are listed on the NASDAQ and all prices are listed in US Dollars. NanoVibronix employs 11 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.84 |
|---|---|
| 52-week range | $0.68 - $4.19 |
| 50-day moving average | $1.10 |
| 200-day moving average | $1.41 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.84 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-23) | -22.22% |
| 3 months (2021-10-26) | -41.26% |
| 6 months (2021-07-26) | -55.79% |
| 1 year (2021-01-26) | -41.26% |
|---|---|
| 2 years (2020-01-24) | -70.73% |
| 3 years (2019-01-25) | 3.4338 |
| 5 years (2017-01-24) | 5.96 |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $214,000 |
| Return on assets TTM | -42.79% |
| Return on equity TTM | -213.94% |
| Profit margin | 0% |
| Book value | $0.31 |
| Market capitalisation | $23.8 million |
TTM: trailing 12 months
We're not expecting NanoVibronix to pay a dividend over the next 12 months.
Over the last 12 months, NanoVibronix's shares have ranged in value from as little as $0.68 up to $4.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NanoVibronix's is 0.0735. This would suggest that NanoVibronix's shares are less volatile than average (for this exchange).
NanoVibronix, Inc. , through its subsidiary, NanoVibronix Ltd. , focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.